Elise: I know that you’re not personally involved in The UCLA Kidney Health Program but wanted to get your perspective on some of its work on behalf of patients diagnosed with chronic kidney disease (CKD). UCLA describes the program as a multi-discipline effort working to bring new and innovative techniques to a range of kidney… Continue reading The Importance of Earlier-Stage Kidney Care and Why PCPs are the Key.
Elise: In our first conversation, we acknowledged the recent debates over removing race from kidney function equations. You were a strong proponent of that action. Based on comments we received, our readers want to more deeply understand the context around your position. Can you provide more color for why removing race is so important? … Continue reading Why we need to remove race from kidney function equations.
Introduction As our readers know, the primary reason for the existence of this Well FilteredTM blog is to bring into focus the latest thinking and perspectives, innovations, and methods for promoting and advancing global kidney health. In some of our previous blog posts, we’ve discussed the societal need to address racial, social, behavioral and economic… Continue reading Should race ever play a role in health care?
Introduction Bringing any new medical product or service to market is quite difficult. Bringing a new or emerging healthcare technology to market is that much more complicated, with an end-to-end commercialization process that includes robust research and development, clinical trials, data collection and analysis, the regulatory pathway and reimbursement. It is predominantly believed that navigating… Continue reading Getting FDA approval, a base hit.
Getting reimbursement, that’s the ball game.
Introduction Over the past few months, I’ve talked to various healthcare influencers about the meaning and implementation of Value-Based Care (VBC), primarily doctors. To get a full-bodied perspective, we thought it best to now bring some external, yet experienced points-of-view, from ‘healthcare outsiders.’ That’s why today’s blog, our second in a planned series of three… Continue reading Is there real value in value-based care?
Introduction For our first blog of 2022, we begin our 3-part series on value-based care and its intersection points with other healthcare strategies and with the healthcare ecosystem, at large. American healthcare faces increasing challenges, including insufficient and inequitable access to care and coverage, the instability of publicly-funded programs, a dated infrastructure, and lagging use… Continue reading A SPECIAL, NEW YEAR INVESTIGATIVE BLOG: Making Sense of Population Health, Precision Medicine & Value-Based Care with Mount Sinai’s
Dr. Arshad Rahim
Introduction Chronic kidney disease (CKD) is highly correlative with cardiovascular risk, demonstrated in the form of coronary artery disease, heart failure, or sudden cardiac death. Cardiovascular events are higher in patients with early CKD compared with the general population, and more so with patients who are in its advanced stages. Cardiovascular complications are actually the… Continue reading An “Inside Look” at Precision Medicine, Cardiovascular & Kidney Disease: We Get It Straight from Bayer’s,
Dr. Amit Sharma
Introduction Americans spent $3.6 trillion dollars on healthcare in 2018. Medical spending as a percentage of US GDP was near 18% in that same year.1 And within that larger healthcare picture, kidney disease looms large, with incomplete diagnosis, insufficient risk stratification, ineffective treatment implementation, poor health outcomes and a high price tag for patients, employers… Continue reading A “How To” Playbook for Disrupting Kidney Care: Our Live Chat with the National Kidney Foundation’s Chief Medical Officer
Introduction Historically, there have not been many promising or positive clinical trials for kidney health. In recent years, kidney health has become an area of focus with therapeutic trials that are exploring the potential detection, prevention and treatment of kidney disease. Recently, I discussed kidney clinical studies with a clear expert on the topic, Katherine… Continue reading Are Kidney-Focused Clinical Studies Finally Hitting Their Groove? The Trials to Watch & Why
3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model By Elise Wilfinger 7.27.21 “That’s why I joined forces with James (James McCullough, CEO & Board Member), Michael (Michael Donovan, Chief Medical Officer), Fergus (Fergus Fleming, Chief Technology Officer) and leading nephrologists (Steve Coca, Girish Nadkarni). And why we’ve been… Continue reading 3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model